Kingsley L. Taft
Corporate Officer/Principal bei Goodwin Procter LLP
Profil
Kingsley L.
Taft is currently a Partner at Goodwin Procter LLP since 2004.
Prior to this, he worked as a Secretary at Semma Therapeutics, Inc.
Aktive Positionen von Kingsley L. Taft
Unternehmen | Position | Beginn |
---|---|---|
Goodwin Procter LLP
Goodwin Procter LLP Investment ManagersFinance Goodwin Procter LLP is a law firm which provides advice to companies in public and private enterprises. It provides services to financial, life sciences, private equity, real estate, and technolgy industries. The company was founded in 1912 and is headquartered in Boston, MA. | Corporate Officer/Principal | 01.06.2004 |
Ehemalige bekannte Positionen von Kingsley L. Taft
Unternehmen | Position | Ende |
---|---|---|
Semma Therapeutics, Inc.
Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | Unternehmenssekretär | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Goodwin Procter LLP
Goodwin Procter LLP Investment ManagersFinance Goodwin Procter LLP is a law firm which provides advice to companies in public and private enterprises. It provides services to financial, life sciences, private equity, real estate, and technolgy industries. The company was founded in 1912 and is headquartered in Boston, MA. | Finance |
Semma Therapeutics, Inc.
Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | Health Technology |